Trials / Completed
CompletedNCT02554279
MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population
A Randomized, Assessor-blind Trial Comparing MENOPUR® (Menotropins for Injection) and Recombinant FSH (Follicle Stimulating Hormone) in a GnRH Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 620 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- 21 Years – 35 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to demonstrate non-inferiority of MENOPUR® versus recombinant Follicle Stimulating Hormone (rFSH) (Gonal-f®) with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation (COS) following GnRH treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | menotropin | |
| DRUG | recombinant FSH |
Timeline
- Start date
- 2015-08-31
- Primary completion
- 2017-01-26
- Completion
- 2017-02-02
- First posted
- 2015-09-18
- Last updated
- 2023-09-21
- Results posted
- 2018-03-02
Locations
35 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02554279. Inclusion in this directory is not an endorsement.